Patients with recurrent thrombosis
| Variable . | Patients with second thrombosis (N = 86) . |
|---|---|
| Age at second thrombosis, median (min, max) | 14.4 (0.1, 22.1) |
| Sex, n (%) | N=86 |
| Female | 43 (50.0) |
| Male | 43 (50.0) |
| Race, n (%) | N=86 |
| Asian | 4 (4.7) |
| Black | 17 (19.8) |
| White | 58 (67.4) |
| Other | 7 (8.2) |
| Ethnicity, n (%) | N=86 |
| Hispanic | 3 (3.5) |
| Non-Hispanic | 83 (96.5) |
| Anticoagulant at the time of recurrent VTE, n (%) | n = 30 |
| Enoxaparin | 16 (53.3) |
| Rivaroxaban | 6 (20.0) |
| UFH | 3 (10.0) |
| Apixaban | 1 (3.3) |
| Fondaparinux | 1 (3.3) |
| Rivaroxaban, ASA | 1 (3.3) |
| Warfarin | 1 (3.3) |
| Warfarin, enoxaparin | 1 (3.3) |
| Days between first and second thrombosis, median (min, max) | 295.0 (1.0, 3600.0) |
| Variable . | Patients with second thrombosis (N = 86) . |
|---|---|
| Age at second thrombosis, median (min, max) | 14.4 (0.1, 22.1) |
| Sex, n (%) | N=86 |
| Female | 43 (50.0) |
| Male | 43 (50.0) |
| Race, n (%) | N=86 |
| Asian | 4 (4.7) |
| Black | 17 (19.8) |
| White | 58 (67.4) |
| Other | 7 (8.2) |
| Ethnicity, n (%) | N=86 |
| Hispanic | 3 (3.5) |
| Non-Hispanic | 83 (96.5) |
| Anticoagulant at the time of recurrent VTE, n (%) | n = 30 |
| Enoxaparin | 16 (53.3) |
| Rivaroxaban | 6 (20.0) |
| UFH | 3 (10.0) |
| Apixaban | 1 (3.3) |
| Fondaparinux | 1 (3.3) |
| Rivaroxaban, ASA | 1 (3.3) |
| Warfarin | 1 (3.3) |
| Warfarin, enoxaparin | 1 (3.3) |
| Days between first and second thrombosis, median (min, max) | 295.0 (1.0, 3600.0) |
Data indicate characteristics, anticoagulation medications, and days between events.
ASA, aspirin; UFH, unfractionated heparin.